Cardiac hypertrophy is enhanced in PPARα-/- mice in response to chronic pressure overload

被引:111
|
作者
Smeets, Pascal J. H. [1 ]
Teunissen, Birgit E. J. [1 ]
Willemsen, Peter H. M. [1 ]
van Nieuwenhoven, Frans A. [1 ]
Brouns, Agnieszka E. [2 ]
Janssen, Ben J. A. [2 ]
Cleutjens, Jack P. M. [3 ]
Staels, Bart [4 ,5 ,6 ]
van der Vusse, Ger J. [1 ]
van Bilsen, Marc [1 ]
机构
[1] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Physiol, NL-6200 MD Maastricht, Netherlands
[2] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Pharmacol & Toxicol, NL-6200 MD Maastricht, Netherlands
[3] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Pathol, NL-6200 MD Maastricht, Netherlands
[4] INSERM, Unite 545, F-59019 Lille, France
[5] Inst Pasteur, Dept Atherosclerose, F-59019 Lille, France
[6] Inst Pasteur, Fac Pharm, F-59019 Lille, France
关键词
PPAR alpha; pressure-overload; hypertrophy; metabolism; fibrosis; inflammation;
D O I
10.1093/cvr/cvn001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Peroxisome protiferator-activated receptor-alpha (PPAR alpha) is a nuclear receptor regulating cardiac metabolism that also has anti-inflammatory properties. Since the activation of inflammatory signalling pathways is considered to be important in cardiac hypertrophy and fibrosis, it is anticipated that PPAR alpha modulates cardiac remodelling. Accordingly, in this study the hypothesis was tested that the absence of PPAR alpha aggravates the cardiac hypertrophic response to pressure overload. Methods and results Male PPAR alpha(-/-) and wild-type mice were subjected to transverse aortic constriction (TAC) for 28 days. TAC resulted in a more pronounced increase in ventricular weight and left ventricular (W) watt thickness in PPAR alpha(-/-) than in wild-type mice. Compared with sham-operated mice, TAC did not affect cardiac function in wild-type mice, but significantly depressed LV ejection fraction and LV contractility in PPAR alpha(-/-) mice. Moreover, after TAC mRNA levels of hypertrophic (atrial. natriuretic factor, alpha-skeletal actin), fibrotic (collagen 1, matrix metalloproteinase-2), and inflammatory (interteukin-6, tumour necrosis factor-alpha, cycto-oxygenase-2) marker genes were higher in PPAR alpha(-/-) than in wild-type mice. The mRNA levels of genes involved in fatty acid metabolism (long-chain acyt-CoA synthetase, hydroxyacyl-CoA dehydrogenase) were decreased in PPAR alpha(-/-) mice, but were not further compromised by TAC. Conclusion The present findings show that the absence of PPAR alpha results in a more pronounced hypertrophic growth response and cardiac dysfunction that are associated with an enhanced expression of markers of inflammation and extracellular matrix remodelling. These findings indicate that PPAR alpha exerts salutary effects during cardiac hypertrophy.
引用
收藏
页码:79 / 89
页数:11
相关论文
共 50 条
  • [31] Cardiac pressure overload induces adrenal medulla hypertrophy and cathecholamine synthesis in mice
    Schneider, J.
    Hein, L.
    Gilsbach, R.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2010, 381 : 15 - 15
  • [32] Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis
    Gao, Xiao-Ming
    Wong, Geoffrey
    Wang, Binghui
    Kiriazis, Helen
    Moore, Xiao-Lei
    Su, Yi-Dan
    Dart, Anthony
    Du, Xiao-Jun
    JOURNAL OF HYPERTENSION, 2006, 24 (08) : 1663 - 1670
  • [33] Caspase Inhibition Prevents Hypertrophy and Improves Cardiac Function with Chronic Pressure Overload
    Park, Misun
    Lee, Jung Ah
    Gao, Shumin
    Yoon, SeongHun
    Xie, Lai-Hua
    Charles, Ludny
    Leibovich, Samuel J.
    Kitsis, Richard N.
    Vatner, Stephen F.
    Vatner, Dorothy E.
    CIRCULATION, 2011, 124 (21)
  • [34] Ablation of cardiac myosin binding-protein C exacerbates pathological hypertrophy in response to pressure overload in mice
    Brickson, SL
    Fitzsimons, DP
    Hacker, T
    Moss, RL
    FASEB JOURNAL, 2006, 20 (05): : A1412 - A1412
  • [35] Cardiac hypertrophy in normotensive mice with enhanced blood pressure variability
    Martinka, P
    Persson, PB
    Stauss, HM
    FASEB JOURNAL, 2003, 17 (05): : A850 - A850
  • [36] PATHOLOGY OF CARDIAC-HYPERTROPHY IN PRESSURE OVERLOAD
    TEZUKA, F
    TAKAHASHI, T
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1976, 40 (10): : 1111 - 1118
  • [37] Calcineurin regulation in pressure overload cardiac hypertrophy
    Li, J
    Guo, HY
    Takagi, G
    Hong, C
    Karoor, V
    West, M
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2003, 30 (07) : A40 - A41
  • [38] Microtubule stabilization in pressure overload cardiac hypertrophy
    Sato, H
    Nagai, T
    Kuppuswamy, D
    Narishige, T
    Koide, M
    Menick, DR
    Cooper, G
    JOURNAL OF CELL BIOLOGY, 1997, 139 (04): : 963 - 973
  • [39] Nifedipine Inhibits Cardiac Hypertrophy and Left Ventricular Dysfunction in Response to Pressure Overload
    Ago, Tetsuro
    Yang, Yanfei
    Zhai, Peiyong
    Sadoshima, Junichi
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2010, 3 (04) : 304 - 313
  • [40] Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload
    Li, Wei-ming
    Zhao, Yi-fan
    Zhu, Guo-fu
    Peng, Wen-hui
    Zhu, Meng-yun
    Yu, Xue-jing
    Chen, Wei
    Xu, Da-chun
    Xu, Ya-wei
    CLINICAL SCIENCE, 2017, 131 (02) : 141 - 154